Know Labs (KNW) has issued an update.
In a significant development for investors, on August 15, 2024, a company launched a registered direct offering, selling over 6 million units at $0.26 each, raising a total of $1.655 million. These units include shares of common stock and warrants to purchase additional shares. The funds are earmarked for the advancement of KnowU glucose monitoring products, among other corporate needs. Additionally, the company has entered into agreements with advisors, granting them a right of first refusal for future equity offerings and compensating them with a cash fee and warrants. This move could signal a strategic expansion and growth phase, potentially stirring interest in the financial markets.
For detailed information about KNW stock, go to TipRanks’ Stock Analysis page.
